INTERIM REPORT
1 JANUARY – 31 MARCH 2021
We strive to improve people's lives
SEK 1,736 m
NET SALES
SEK 326 m
EBITA
200 %
EARNINGS GROWTH R12 MONTHS
122 %
P/WC
Strong start to the year and two strategic acquisitions
The world is still under the grip of the COVID-19 pandemic. Our subsidiaries continue to do a great job of generating business and responding to the needs of our customers. Sales in the first quarter of the year increased by 65 percent to SEK 1,736 million and earnings, EBITA, increased by 209 percent to SEK 326 million and we strengthened the EBITA margin to 18.8 percent. After the end of the quarter, we completed two major acquisitions, Vision Ophthalmology Group (VOG) and Healthcare 21 (HC21). Together, the acquisitions are expected to increase our annual net sales by more than 40 percent, corresponding to approximately SEK 2.4 billion, to approximately SEK 7.6 billion.
A leading player in Life Science
AddLife is a listed Swedish Medtech company active on the European market. AddLife owns and acquires companies in niche segments with offerings aimed primarily at the healthcare sector, from research to medical care. The subsidiaries are divided into two business areas. Labtech offers products, solutions and a wide range of diagnostic services, biomedical research and laboratory analysis. Medtech offers products, solutions and services in medical technology and home care.
Increased acquisition activity through two strategic acquisitions after the end of the quarter
After the end of the quarter, we completed two major acquisitions, Vision Ophthalmology Group (VOG) and Healthcare 21 (HC21). Together, the acquisitions are expected to increase our annual net sales by more than 40 percent, corresponding to approximately SEK 2.4 billion, to approximately SEK 7.6 billion and EBITA is expected to increase by about 38 percent to approximately SEK 1.1 billion. The acquired companies will form their own subgroups with existing management and will belong to the Medtech business area. The acquisitions make AddLife a true European player with more than half of net sales in markets outside the Nordic region.
